Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Viking Therapeutics (VKTX) Profit After Tax: 2014-2024

Historic Profit After Tax for Viking Therapeutics (VKTX) over the last 11 years, with Dec 2024 value amounting to -$110.0 million.

  • Viking Therapeutics' Profit After Tax fell 264.02% to -$90.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$237.4 million, marking a year-over-year decrease of 139.43%. This contributed to the annual value of -$110.0 million for FY2024, which is 28.02% down from last year.
  • Per Viking Therapeutics' latest filing, its Profit After Tax stood at -$110.0 million for FY2024, which was down 28.02% from -$85.9 million recorded in FY2023.
  • Over the past 5 years, Viking Therapeutics' Profit After Tax peaked at -$39.5 million during FY2020, and registered a low of -$110.0 million during FY2024.
  • Its 3-year average for Profit After Tax is -$88.2 million, with a median of -$85.9 million in 2023.
  • Data for Viking Therapeutics' Profit After Tax shows a maximum YoY tumbled of 53.21% (in 2020) over the last 5 years.
  • Viking Therapeutics' Profit After Tax (Yearly) stood at -$39.5 million in 2020, then slumped by 39.23% to -$55.0 million in 2021, then declined by 25.24% to -$68.9 million in 2022, then decreased by 24.73% to -$85.9 million in 2023, then dropped by 28.02% to -$110.0 million in 2024.